Establishment of chemotherapeutic strategy focused on the mechanism of c-Met activation in hepatocellular carcinoma.
| Project/Area Number |
26462037
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
國土 典宏 東京大学, 医学部附属病院, 教授 (00205361)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 肝細胞癌 / c-Met / 化学療法剤 / 転移 |
|---|
| Outline of Final Research Achievements |
Establishment of new chemotherapy is required for the treatment of hepatocellular carcinoma (HCC) to improve the bad prognosis of patients with unresectable cancer and the frequent recurrence after surgery. In the present study, the effect of c-Met inhibitor on the growth and the invasion of HCC cells was investigated. SU11274, a c-Met inhibitor, was suppressed the proliferation and the invasion of HCC cells in vitro. In addition, the HCC cells treated with SU11274 enhanced its adhesiveness via the up-regulation of e-cadherin. These results suggest that c-Met is a good target for the development of new chemotherapeutic agent.
|
Report
(4 results)
Research Products
(20 results)
